Research programme: bacterial and viral infection therapeutics - Anacor/GlaxoSmithKline

Drug Profile

Research programme: bacterial and viral infection therapeutics - Anacor/GlaxoSmithKline

Latest Information Update: 05 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Anacor Pharmaceuticals
  • Developer Anacor Pharmaceuticals; GlaxoSmithKline
  • Class Organic boron compounds; Small molecules
  • Mechanism of Action Amino acyl tRNA synthetase inhibitors; Hepatitis C protease inhibitors; Leucyl-tRNA synthetase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections; Gram-negative infections
  • Research Hepatitis C; Viral infections

Most Recent Events

  • 24 Jun 2016 Anacor Pharmaceuticals has been acquired by Pfizer
  • 20 Feb 2014 Development is ongoing in the USA
  • 09 Oct 2012 Development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top